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Abstract: As populations age, heart failure (HF) is becoming increasingly common, and in 
addition to a high burden of morbidity and mortality, HF has an enormous ﬁ  nancial impact. 
Though disproportionately affected by HF, the elderly are less likely to receive recommended 
therapies, in part because clinical trials of HF therapy have ignored outcomes of importance to this 
population, including impaired cognitive function (ICF). HF is associated with ICF, manifested 
primarily as delirium in hospitalized patients, or as mild cognitive impairment or dementia in 
otherwise stable outpatients. This association is likely the result of shared risk factors, as well 
as perfusion and rheological abnormalities that occur in patients with HF. Evidence suggests 
that these abnormalities may be partially reversible with standard HF therapy. The clinical con-
sequences of ICF in HF patients are signiﬁ  cant. Clinicians should consider becoming familiar 
with screening instruments for ICF, including delirium and dementia, in order to identify patients 
at risk of nonadherence to HF therapy and related adverse consequences. Preliminary evidence 
suggests that optimal HF therapy in elderly patients may preserve or even improve cognitive 
function, though the impact on related outcomes remains to be determined.
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Introduction
The term “cardiogenic dementia” was introduced in 1977 and although the concept 
was poorly developed at that time, it did identify a link between impaired cognitive 
function and cardiac disease (Lancet Editorial 1977).
The worldwide burden of cardiovascular disease is substantial and now accounts 
for approximately 30% of deaths from chronic illness globally (Strong et al 2005). 
Despite a decline in cardiovascular mortality in developed countries over the last three 
decades, the burden of heart failure (HF) has risen (Rich 2001; Strong et al 2005). HF 
develops when cardiac output is insufﬁ  cient to meet metabolic requirements, usually 
in the setting of functional or structural cardiac defects (Colluci and Braunwald 2005). 
HF occurs primarily in patients aged 55 years and over, and its prevalence rises with 
increasing age (American Heart Association 2002; Bleumink et al 2004; Lee et al 
2004). In the prospective cohort Rotterdam study, the prevalence of HF rose from 
0.9% in persons aged 55 to 64 years, to 4% in persons aged 65–74 years, 9.7% in 
persons aged 75–84 years, and 17.4% in persons aged 85 years and over (Bleumink 
et al 2004). The lifetime risk of developing HF is approximately 20% in men and 
women who reach the age of 80 years (American Heart Association 2002). The rising 
prevalence of HF is driven in large part by population aging and the longer survival 
of adult patients with hypertension and ischemic heart disease (Rich 2001; Strong 
et al 2005). Between 2001 and 2030, the number of elderly persons over the age of 
65 will double, with the greatest proportional increase occurring among octogenarians 
(Statistics Canada 2001). Over that thirty-year span, the prevalence of HF will likely 
quadruple (Rich 2001).Clinical Interventions in Aging 2007:2(2) 210
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Despite advances in management, HF remains associated 
with substantial mortality, morbidity, and economic impact, 
particularly among elderly persons (Rich 2001). Elderly HF 
patients are less likely to receive recommended therapies, 
in part due to their under-representation in clinical trials, as well 
as excessive concerns about adverse drug events (Fuat et al 
2003). In addition, by focusing on mortality and hospitalization, 
HF trials have neglected outcomes of relevance to the frail 
elderly, such as impaired cognitive function (ICF.) There are 
two predominant syndromes of ICF. Acute and ﬂ  uctuating ICF, 
known as delirium, can be precipitated by an underlying medi-
cal illness. Delirium may be present in as many as one quarter 
of elderly patients presenting to hospital and may develop in 
over 50% during hospitalization, and is therefore most likely 
to occur in the setting of decompensated HF (Pi-Figueras et al 
2004; Inouye 2006). Chronic ICF can be recognized in patients 
with stable HF and is referred to as dementia if it interferes 
with a person’s independent function. Mild cognitive impair-
ment (MCI) or cognitive impairment but no dementia (CIND) 
are considered to be borderzone conditions between normal-
ity and dementia, if independent function is retained despite 
documented cognitive deﬁ  cits (Petersen and O’Brien 2006). 
Dementia affects approximately 8% of the Canadian population 
and, as with HF, its prevalence increases with age (Canadian 
Study on Health and Aging 1994). The prevalence of CIND is 
approximately twice that of dementia and is associated with 
higher mortality and a greater likelihood of developing dementia 
(Tuokko et al 2003). An important distinction between delirium 
and dementia is that delirium is often reversible if the underlying 
precipitant is diagnosed and treated (although recovery may be 
delayed for weeks or even months), while dementia is chronic 
and usually progressive (Inouye 2006).
As populations age, with the prevalence of both HF and 
ICF rising with age, the simultaneous occurrence of these 
two conditions in the same individual will become more 
frequent. Furthermore, recent studies have identiﬁ  ed a strong 
and possibly causal relationship between HF and ICF. The 
purpose of this review is to describe the epidemiology of this 
association, outline potential underlying mechanisms, and 
discuss the relevance of ICF to the clinical management of 
HF, primarily focusing on elderly patients.
Epidemiology of impaired cognitive 
function in older persons with heart 
failure
An association between HF in older persons and ICF has 
been described in several recent studies, though few have 
attempted to distinguish delirium from dementia. In a review 
of 156 acute HF episodes occurring in a cohort of patients 
aged 83.2 ± 9.0 years and admitted to convalescence homes 
in ﬁ  ve US states, acute confusion consistent with delirium 
was a presenting feature in 35.3% of cases (Hutt et al 2003). 
A high prevalence of ICF has been documented in older 
patients hospitalized or recently discharged from acute care 
facilities with HF. In a cross-sectional study of 57 consecutive 
inpatients with no prior history of dementia, with a mean age 
of 76.7 years, New York Heart Association (NYHA) class 
II-III HF symptoms, and mean left ventricular (LV) ejection 
fraction of 44.7 ± 0.6%, 53% scored below the commonly 
accepted cut-off for dementia of 24/30 on the Mini Mental 
State Examination (MMSE) (Folstein et al 1975; Zuccala 
et al 1997). Lower MMSE scores were associated with more 
severe LV systolic dysfunction. In a case-control study, the 
neuropsychological battery of the Cambridge Examination 
for Mental Disorders of the Elderly (CAMCOG) was admin-
istered to 50 consecutive hospitalized patients aged 67.3 ± 0.9 
years and with NYHA III-IV HF and (Almeida and Tamai 
2001a). Thirty outpatients aged 76.7 ± 1.5 years without HF 
and with normal LV function served as controls. None of the 
participants had a prior diagnosis of dementia. Despite their 
lower age, a greater number of HF patients scored below the 
threshold for dementia than did controls (74% vs. 30%, 
p < 0.001), and the severity of CI was related to the severity 
of LV systolic dysfunction. In a study of 515 elderly patients 
aged 75 ± 7 years, with no prior diagnosis of dementia, who 
were hospitalized with a primary cardiac diagnosis, cogni-
tion was worse among those with HF compared with those 
without (Trojano et al 2003). The severity of CI correlated 
with the severity of NYHA symptoms.
The studies described above suggest that ICF is com-
mon in older patients with acute HF, and that the severity 
of cognitive dysfunction is related to the severity of HF 
symptoms and LV systolic dysfunction. The presence of ICF 
in so many older patients soon after an episode of acute HF 
suggests that many may have been experiencing delirium. 
However, a number of studies of nonhospitalized and pre-
sumably stable community-dwelling elderly persons suggest 
that a history of HF is also associated with a greater risk of 
chronic ICF or dementia. In a randomly selected sample, 
1075 elderly Italians aged 73.9 ± 6.2 years were assessed 
clinically for a history of HF and ICF as indicated by a MMSE 
score of less than 24/30 (Cacciatore et al 1998). Those with 
a history of HF were more likely to have ICF than those 
without (adjusted OR 1.96; 95% CI 1.07–3.58). The Berlin 
Aging Study assessed 516 randomly community-dwelling Clinical Interventions in Aging 2007:2(2) 211
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persons with a mean age of 84.9 ± 8.6 years, 206 of which 
were followed over four years (Verhaeghen et al 2003). HF 
was associated with poorer cognition at baseline. The rate 
of cognitive decline over four years was not signiﬁ  cantly 
different among persons with HF, coronary artery disease, 
diabetes, or controls without clinical cardiovascular disease, 
likely reﬂ  ecting attrition of very elderly persons with severe 
HF and thus more severe ICF. The Helsinki Aging Study 
followed a randomly selected sample of 650 community-
dwelling seniors stratiﬁ  ed at inception into three groups: 
aged 75 years (239 persons), aged 80 years (212 persons), 
and aged 85 years (199 persons) (Tilvis et al 2004). A neu-
rologist assessed baseline cognition and cognitive decline 
was deﬁ  ned either as deterioration of 4 or more points on 
the MMSE or a worse classiﬁ  cation in the Clinical Dementia 
Rating scale (Morris 1993). A history of HF was associated 
with cognitive decline and mortality over ﬁ  ve years (Rela-
tive risk [RR] 1.83, 95% CI 1.02–3.27, and RR 1.76, 95% 
CI 1.23–2.51, respectively). Cardiovascular disorders did not 
predict cognitive decline over ten years, though by the end 
of the study 61% of participants had died. The Kungsholmen 
project followed 1301 community-dwelling seniors aged 
81.5 ± 4.9 years with no prior history of dementia, 205 of 
whom had a history of HF (Qiu et al 2006). After an average 
follow-up of 5 years, those with a history of HF were more 
likely to develop dementia, including Alzheimer’s disease 
(Hazard ratio [HR] 1.84, 95% CI 1.35–2.51, and 1.80, 95% CI 
1.25–2.61). In a cross-sectional analysis of baseline cognitive 
assessments of 3425 elderly persons aged 74.0 ± 5.6 years 
in the Italian Longitudinal Study, those with a history of HF 
were more likely to be classiﬁ  ed as having CIND (OR 1.73, 
95% CI 1.11–2.68) (DiCarlo et al 2000).
The data presented above supports an association between 
ICF and a history of HF in elderly persons, and suggests that 
both acute delirium and chronic ICF, including CIND and 
dementia, can occur in these patients.
Pathophysiology of impaired 
cognitive function in older patients 
with heart failure
Shared risk factors
The association between ICF and HF in older persons is multi-
factorial and includes shared risk factors for both chronic ICF 
and delirium, as well as factors arising from LV dysfunction per 
se. Risk factors for HF, such as atherosclerosis, hypertension, 
and diabetes mellitus, can also lead to chronic ICF (Breteler et al 
1994; Skoog et al 1996; Ott et al 1999; Heckman and McKelvie 
2000; Roman 2004; Whitmer et al 2005; Cukierman et al 2005). 
In patients with vascular risk factors, ICF can develop as a result 
of strokes affecting key cerebral structures (strategic strokes), 
multiple strokes, or periventricular ischemic leukoencepha-
lopathy (Roman 2003a). Vascular risk factors have also been 
implicated in the development of Alzheimer’s disease (Skoog 
et al 1996; Hofman et al 1997; Ott et al 1999).
Older patients with decompensated HF are also at risk for 
delirium. Risk factors that predispose to delirium in hospital-
ized elderly patients include pre-existing chronic ICF, visual 
or hearing impairment, dehydration, and illness severity, while 
precipitants of delirium include the use of urinary catheters 
and other forms of restraint, malnutrition, the introduction of 
three or more new medications, and iatrogenic events (Inouye 
et al 1993; Inouye and Charpentier 1996). The occurrence of 
one or more of these risk factors is common in older patients 
hospitalized with HF (Zuccala et al 2005a). Furthermore, 
medications used to manage HF may also increase the likeli-
hood of delirium. Furosemide and digoxin have measurable 
anticholinergic activity, and an elevated anticholinergic burden 
from prescribed medications has been associated with post-
operative delirium (Tune et al 1993; Tune 2001). Digoxin can 
cause delirium at serum concentrations generally considered 
therapeutic and in the absence of classical electrocardiographic 
abnormalities (McDonnell Cooke 1993). In a cross-sectional 
study of hospitalized patients with NYHA II-IV HF, the use 
of digoxin and furosemide was associated with memory dif-
ﬁ  culties, though it is unclear whether these reﬂ  ected illness 
severity or adverse drug events (Antonelli Incalzi et al 2003). 
Other cardiovascular medications that may be prescribed to 
elderly HF patients, including β-blockers, nondihydropyridine 
calcium-channel blockers, amiodarone and other antiar-
rhythmic agents, have been associated with the occurrence 
of neuropsychiatric disturbances, including delirium (Keller 
and Frishman 2003).
Heart failure and cerebral perfusion
There is mounting evidence that the association between HF 
and ICF reﬂ  ects more than shared risk factors. HF is a risk 
factor for stroke, which may complicate as many as 5% of 
hospitalizations of patients with HF, and which can result from 
a number of mechanisms (Kannel et al 1983; Brown and Cleland 
1998; Loh et al 1999). Patients with HF are predisposed to 
cardiogenic thromboembolism. In the setting of severe LV 
dysfunction and dilation of cardiac chambers, sluggish blood 
ﬂ  ow may promote thrombus formation (Lip and Gibbs 1999). 
HF is associated with impaired endothelial function, which 
may promote platelet adhesion to the endothelium and thus Clinical Interventions in Aging 2007:2(2) 212
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facilitate thrombosis (Kubo et al 1991; Lip and Gibbs 1999). 
Rheological abnormalities in patients with HF include activa-
tion of platelets and of the coagulation cascade, and are most 
pronounced in the setting of severe LV systolic dysfunction 
(Jafri et al 1993; Sbaroumi et al 1994; Hoffmeister et al 1999; 
Gibbs et al 2001; Chin et al 2003). The combination of 
abnormal intracardiac blood ﬂ  ow, endothelial dysfunction, 
and rheological abnormalities satisfy Virchow’s triad and 
suggest that HF, particularly in the setting of LV systolic 
dysfunction, is a hypercoagulable state (Lip and Gibbs 1999). 
Furthermore, as many as 20% of strokes in HF patients may 
occur when transient myocardial ischemia or arrhythmias 
cause sudden reductions in cardiac output, leading to water-
shed infarction of cerebral territories with precarious blood 
supply, or of major arterial territories already compromised 
by coincident arterial stenosis (Howard et al 1987; MacKenzie 
2000). The consequences of strokes are more signiﬁ  cant in 
patients with a history of HF. Imaging studies reveal that 
patients with impaired LV systolic function suffer larger 
infarcts as well as more symptomatic watershed infracts than 
controls with preserved LV systolic function (Pullicino et al 
2001). HF has been identiﬁ  ed as a risk factor for the develop-
ment of post-stroke dementia (Leys et al 2005).
In addition to stroke, HF can lead to more diffuse brain 
injury. Using magnetic resonance imaging (MRI), the brains 
of nine stable HF patients aged 50 ± 10 years and with LV sys-
tolic dysfunction were compared with those of twenty-seven 
healthy and matched controls (Woo et al 2003). Signiﬁ  cant 
cerebral atrophy, affecting the deep and inferior temporal 
lobes, parahippocampal gyrus, and frontal lobes, particularly 
of the right cerebral hemisphere, was observed in the patients 
with HF, though no cognitive testing was performed to 
assess the clinical signiﬁ  cance of these ﬁ  ndings. In another 
MRI study, twenty patients with HF due to idiopathic dilated 
cardiomyopathy aged 40.5 ± 7.8 years were compared with 
twenty healthy matched controls (Schmidt et al 1991). Patients 
with HF had more severe cortical atrophy and enlargement 
of cerebral ventricles than controls, with the duration of HF 
predicting the severity of the lesions. Morphological abnor-
malities detected by MRI correlated with worse performance 
in cognitive tests for memory, learning, and vigilance. Finally, 
a history of HF has been associated with the development of 
periventricular leukoaraiosis, an established risk factor for 
ICF (Tarvonen-Schröder et al 1996; Roman 2003b).
In summary, HF is associated with various forms of brain 
injury. Acute strokes can result from cardiogenic embolism or 
transient hemodynamic disturbances and have more signiﬁ  -
cant clinical consequences, including a greater risk of ICF. HF 
is also associated with more widespread and diffuse lesions. 
These lesions may develop gradually from chronic ischemia 
due to cerebral perfusion abnormalities (Roman 2003a). Thus 
far, the literature has largely attributed cerebral hypoperfusion 
to the hemodynamic consequences of HF, such as reduced 
effective circulating volume and relative hypotension (Zuccala 
et al 2001; Bennet et al 2005). However, the regulation of 
cerebral perfusion also depends on neurohormonal and 
humoral factors, some of which are potentially reversible. 
Cerebral hypoperfusion in patients 
with heart failure
Cerebral hypoperfusion is associated with ICF in patients with 
HF. Using single-photon emission computed tomography 
(SPECT), cerebral perfusion in seventeen stable HF patients 
aged 73.7 ± 5.4 years, with LV ejection fraction less than 50%, 
and NYHA II-III functional capacity, was compared with that 
of eighteen age-matched healthy controls (Alves et al 2005). 
Patients with HF demonstrated reduced perfusion in a number 
of regions including the posterior cortices, which appeared to 
correlate with impaired visual memory. Studies of younger 
patients demonstrate that cognition often improves follow-
ing cardiac transplantation, and that these improvements are 
associated with increased cerebral perfusion as measured by 
transcranial doppler assessments of middle cerebral arterial 
ﬂ  ow and cerebral SPECT (Gruhn et al 2001; Bennet and Sauvé 
2003; Massaro et al 2006). A study of 29 patients aged 52 ± 12 
years and with severe LV systolic dysfunction demonstrated 
near-normalization of cognitive evoked potentials following 
implantation of LV assist devices, correlating with improve-
ments in cardiac index (Zimpfer et al 2006).
In addition to cardiac output, cerebral perfusion is medi-
ated by a number of other factors, including blood pressure, 
blood vessel radius and length, and blood viscosity η, and 
which are described by Poiseuille’s law (Román 2003a):
Flow
pressure radius
length
=
××
××
π
η
4
8
.
A number of studies have suggested that in comparison with 
age-matched controls, blood viscosity is elevated in patients 
with HF (Sbarouni et al 1994; Hoffmesiter et al 1999; Gibbs et 
al 2001). Viscosity is greatest among patients with more severe 
NYHA functional capacity and LV systolic dysfunction.
Another important determinant of cerebral perfusion is 
vessel radius, which is regulated by a number of neurohormonal 
mechanisms and humoral factors. Mediators of vasodilation 
include cholinergic neurons arising from the nucleus basalis 
of Meynert, bradykinin, nitric oxide, potassium, and Clinical Interventions in Aging 2007:2(2) 213
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magnesium (Román 2003a). Mediators of vasoconstriction 
include norepinephrine, serotonin, calcium, arterial 
hypocapnea and hyperoxia. In healthy individuals, an auto-
regulatory mechanism exists to balance these mediators and 
thus maintain perfusion over a wide range of systemic blood 
pressure and cerebral metabolic demands. In older patients, 
vascular architecture is disrupted through a combination of 
age-associated changes and vascular risk factors, resulting 
in narrower, longer and more tortuous vessels, and increased 
susceptibility to hypoperfusion resulting from systemic 
hemodynamic disturbances (Román 2003a). The frontal lobes 
are particularly vulnerable to these changes. The capacity 
for cerebral autoregulation appears to be further reduced in 
patients with HF. Cerebrovascular reactivity, as measured 
by changes in middle cerebral arterial ﬂ  ow in response to 
hypercapnea, was studied in a cohort of 50 patients with HF, 
aged 59 ± 11 years, LV ejection fractions ranging from 12 to 
54%, and NYHA II-IV symptoms (Georgiadis et al 2000). 
In comparison to 20 age-matched and 20 younger healthy 
controls, cerebrovascular reactivity was impaired in patients 
with HF. The severity of LV systolic dysfunction and the 
severity of NYHA functional capacity, were both indepen-
dent predictors of impaired cerebrovascular reactivity.
Another recently hypothesized mechanism leading to 
impaired cerebral perfusion in some HF patients is the 
development of CSF effusions, in an analogous fashion to 
the development of pleural effusions (Caplan 2006). This 
syndrome may present with reduced spontaneous behaviour 
and apathy, and appears to be reversible following the with-
drawal of cerebrospinal ﬂ  uid by lumbar puncture.
Can HF therapy improve cerebral 
perfusion and cognitive function?
A number of neurohormonal axes are activated in patients 
with chronic HF which, when left unchecked, eventually 
result in clinical deterioration. The most important of these 
neurohormonal axes are the renin-angiotensin-aldosterone 
(RAA) axis and the adrenergic system (Colluci and Braunwald 
2005). Medications that antagonize these neurohormonal 
mechanisms, such as ACE inhibitors, angiotensin receptor 
blockers, aldosterone antagonists, and β-blockers, exert 
beneﬁ  cial effects on mortality and morbidity in patients with 
chronic HF, particularly in the setting of LV systolic dysfunc-
tion (Arnold et al 2006). Activation of the RAA axis has been 
implicated in abnormal regulation of cerebral perfusion in the 
setting of hypertension and HF, often resulting in a righward 
shift of cerebral perfusion autoregulation towards higher 
blood pressures and increasing brain susceptibility to ischemia 
(Saavedra et al 2006). Increased circulating angiotensin II 
and aldosterone may impair cerebral perfusion by reducing 
large artery compliance and causing endothelial dysfunction 
as well as cerebral vasoconstriction, the latter being medi-
ated directly by angiotensin II and indirectly by activation of 
the sympathetic nervous system and altered metabolism of 
vasodilatory kinins (Saavedra and Nishimura 1999; Stier 
et al 2002; Moreau et al 2005; Saavedra et al 2006).
A number of small studies suggest that ACE inhibitors 
may have beneﬁ  cial effects on cerebral perfusion. In two of 
these studies, patients with HF primarily due to LV systolic 
dysfunction and NYHA class III and IV functional capacity 
were treated with captopril (Paulson et al 1984; Rajagopalan 
et al 1984). While mean arterial blood pressure fell by 10% 
to 26%, cerebral blood ﬂ  ow, as measured by functional 
imaging, either remained unchanged or increased. In contrast, 
control patients in one of the studies experienced both a fall 
in mean arterial pressure and a reduction in cerebral perfu-
sion (Paulson et al 1984). These observations may extend 
to patients with HF with preserved LV systolic function. 
In a double blind randomized controlled trial of 24 stable 
patients aged on average 74 years, a mean EF of 53 ± 2%, 
and NYHA II to III functional capacity, and who had not 
been taking any cardiovascular medications for two weeks, 
initiation of diuretic therapy with furosemide increased the 
likelihood of post-prandial hypotension associated with a 
reduction in frontal lobe oxygenation, as measured by near-
infrared spectroscopy (Mehagnoul-Schipper et al 2002). In 
contrast, patients randomized to initiation of captopril therapy 
experienced no signiﬁ  cant changes in frontal lobe oxygen-
ation. These observations suggest that the administration of 
ACE-inhibitors can maintain or improve cerebral perfusion. 
Furthermore, angiotensin converting enzyme (ACE) inhibi-
tors and β-blockers may improve blood viscosity in patients 
with HF (Turchetti et al 2002). Preliminary evidence also sug-
gests that ACE inhibitors may improve cognition in patients 
with HF. In an uncontrolled prospective cohort study of 31 
patients aged 67.3 years who were hospitalized with severe 
HF and who were well enough to undergo repeat cognitive 
testing over a 6-week interval, treatment with ACE inhibi-
tors and the judicious use of diuretics was associated with 
improvement in measures of attention (Almeida and Tamai 
2001b). In a retrospective database analysis of 1220 patients 
hospitalized with HF, aged 79 ± 9 years, none of whom 
received ACE inhibitors prior to admission, ACE inhibitor 
use was associated with greater improvements in cognition 
throughout the hospital stay (OR 1.57, 95% CI 1.18–2.08) Clinical Interventions in Aging 2007:2(2) 214
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(Zuccala et al 2005b). Furthermore, a dose-response relation-
ship was observed between improvements in cognition and 
higher ACE inhibitor doses (p value for trend = 0.001). It 
remains unclear whether the improvements observed in these 
two studies can be attributed to ACE inhibitors per se, reﬂ  ect 
the natural history of delirium or better tolerance of these 
medications by relatively less frail individuals. Similar data 
on the effect of angiotensin receptor blockers and aldosterone 
antagonists are lacking at this time.
The effect of other HF therapies on cerebral perfusion 
and cognitive function remain to be evaluated. Modest 
improvements in LV systolic function may result from use 
of β-blockers, aldosterone antagonists, digitalis, and cardiac 
resynchronization, though whether these are associated with 
improved cognition remains to be determined (Kirkwood 
et al 2002; Cleland et al 2005; Frigerio and Roubina 2005). 
Similarly, while circulating norepinephrine levels are elevated 
in patients with HF, particularly in the setting of LV systolic 
dysfunction, it remains to be determined whether β-blockers, 
particularly nonselective β-blockers such as carvedilol, can 
improve cerebral perfusion and cognitive function (Court and 
Perry 2003; Kohno et al 2005; Culluci and Braunwald 2005).
HF, sleep quality, and cognition
Sleep disturbances may result in daytime cognitive dysfunction 
(Bedard et al 1991). Cheyne-Stokes respiration during sleep 
is common in patients with advanced HF, though it remains 
unclear whether this phenomenon is related to the ICF seen 
in these patients, or whether treating them with nocturnal 
oxygen or continuous positive airway pressure can improve 
cognitive function (Andreas et al 1996; Staniforth et al 1998, 
2001). Improved alertness resulting from better sleep has 
been hypothesized as the reason for the beneﬁ  cial effects on 
cognition observed in a trial in which a supervised exercise 
program was administered over eighteen weeks to twenty HF 
patients aged 63 ± 13 years, with NYHA III symptoms and LV 
ejection fraction 35% or less (Tanne et al 2005). Compared 
with matched control patients who did not exercise, those who 
completed the exercise program experienced improvements 
in psychomotor speed and general attention.
Clinical implications of impaired 
cognitive function in older persons 
with heart failure
The impact of CI in patients with HF is substantial and 
includes an increased risk of rehospitalization, progressive 
physical disability, and higher mortality (Zuccala et al 
2001b, 2003; Hutt et al 2003; Rozzini and Sabatinin 2004). 
In community-dwelling elderly patients, ICF may lead to 
nonadherence to recommended therapy, medication mis-
management, failure to recognize early symptoms and seek 
timely medical attention, and HF hospitalization (Vinson et al 
1990; Bennett et al 1997; Chin and Goldman 1997; Cline et al 
1999; Ekman et al 2001). These adverse outcomes may arise 
through a number of mechanisms. Delirium can develop early 
in the course of any acute illness, in patients with previously 
normal cognition as well as those with dementia (Inouye 
2006). Delirium is a nonspeciﬁ  c syndrome that can be trig-
gered by a number of medical conditions, leading to delays 
in the recognition of HF as the underlying precipitant and the 
initiation of appropriate therapy. Furthermore, the develop-
ment of delirium in acute HF may jeopardize the ability even 
for previously cognitively intact patients to recognize their 
illness and make appropriate health care decisions.
Adverse outcomes can also result from the speciﬁ  c types 
of cognitive deﬁ  cits that occur in older patients with HF. A 
systematic review of cognitive testing in patients with HF 
identiﬁ  ed impairments in global measures of cognition, and 
deﬁ  cits in short term memory and the ability to sustain attention 
(Almeida and Flicker 2001). Other studies have demonstrated 
impairments in immediate and delayed memory, executive 
function, verbal ﬂ  uency, attention, processing speed, and 
learning (Antonelli Incalzi et al 2003; Trojano et al 2003; 
Verhoeghen et al 2003; Alves et al 2005; Tanne et al 2005; 
Jefferson et al 2006). Executive dysfunction is associated 
with injury to frontal lobe system which occurs commonly 
in patients with cardiovascular disease, and is characterized 
by difﬁ  culties with disorganized thinking, formulating and 
achieving goals, and problem-solving (Goetz 2003; Roman 
2003b). Clearly, deﬁ  cits in one or more of these domains has 
the potential to impair a patient’s ability to master the complex 
tasks involved in the management of HF, including complying 
with dietary restrictions, prescribed medications, monitoring of 
ﬂ  uid balance and weights, and taking appropriate and timely 
action when symptoms of decompensated HF develop.
Clinicians looking after elderly persons with HF should 
maintain a high index of suspicion for the presence of ICF, 
as data suggest that it is frequently under-diagnosed. Despite 
its high prevalence and incidence among elderly hospital-
ized patients, as many as two thirds of cases of delirium 
may remain unrecognized by physicians (Inouye 2006). 
ICF is also underdiagnosed in stable outpatients with HF. 
In a cohort of 88 consecutive stable outpatients attending a 
specialized hospital-based HF clinic with a mean age of 76 
years and a mean LV ejection fraction of 35%, and only two Clinical Interventions in Aging 2007:2(2) 215
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of whom had been previously diagnosed with ICF, cognitive 
deﬁ  cits were identiﬁ  ed in 39% (St.Onge et al 2004). One 
important reason for the underdiagnosis of ICF in HF patients 
is that commonly used screening tests such as the MMSE 
are insensitive to executive dysfunction (Roman 2003a). 
ICF should be strongly considered when caregivers report 
cognitive difﬁ  culties, changes in personality and behaviour, 
incontinence or gait difﬁ  culties, all of which may suggest 
executive dysfunction in elderly HF patients (Patterson and 
Gass 2001; Roman 2003a).
The most important step in the evaluation of ICF in 
a hospitalized patient is to determine its onset with a 
focused history (Inouye 2006). Acute cognitive decline 
suggests delirium and requires that physicians undertake 
a careful assessment for possible HF, as well as for other 
occult medical illness or medication side effects. Clini-
cians should consider becoming familiar with the CAM, 
a simple yet powerful screening instrument for delirium 
(Inouye et al 1990). Furthermore, while delirium usually 
improves when the underlying causes are identiﬁ  ed and 
treated, the associated cognitive deﬁ  cits may persist for 
weeks to months, well beyond hospital discharge (Cole et al 
2003; McCusker et al 2003). Consequently, even a patient 
whose dyspnea and oedema have improved sufﬁ  ciently to 
consider discharge from hospital may remain too cogni-
tively impaired to beneﬁ  t from educational efforts designed 
to prevent rehospitalization. In order to assess executive 
function, which is associated with the ability to perform 
instrumental daily activities, and is likely to be important 
in strategies to prevent rehospitalization, clinicians should 
consider becoming familiar with brief screening tests for 
executive dysfunction. These include the Trail Making B 
Test (Tombaugh 2004; Lavery et al 2006), CLOX (Royall 
et al 1998), Executive Interview (EXIT-25)(Royall et al 
1992), or Frontal Assessment Battery (FAB)(Dubois et al 
2000). In patients presenting with either acute delirium or 
chronic ICF, referral for further cognitive assessment should 
be considered (Arnold et al 2006).
Therapies shown to be effective in younger patients 
with HF are often withheld from elderly patients. Evidence 
derived from a small number of randomized trials, as well 
as substantial observational data, is consistent in supporting 
the beneﬁ  ts of standard HF therapies, and particularly ACE 
inhibitors and β-blockers, in elderly patients (Arnold et al 
2006). The discussion above suggests that ACE inhibitors 
may be particularly effective in protecting cognitive function. 
Care should be taken to avoid over-diuresis, and digoxin 
should be used sparingly due its potential for side effects 
such as delirium in older patients (McDonnell Cooke 1993). 
For patients with ICF, clinicians should consider directing 
educational interventions for HF management to cognitively 
intact caregivers (Arnold et al 2006). Adherence to prescribed 
therapy may be improved through the use of pill boxes ﬁ  lled 
weekly and supervised by a pharmacist or caregiver, and 
ensuring adequate social support through family members or 
visiting nurses (Papaioannou and Uppaluri 2003). Referral 
of elderly patients with ICF to multidisciplinary HF man-
agement programs should be considered, and involvement 
of primary care physicians is essential (Gonseth et al 2004; 
Arnold et al 2006). In hospitalized patients with HF, risk fac-
tors predisposing to the development of delirium should be 
identiﬁ  ed, as simple and cost-effective maneuvers targeting 
these risk factors have been shown to prevent up to 40% of 
incident cases of delirium in at-risk medical patients (Inouye 
et al 1999).
Conclusion
The coming decades will see a substantial rise in the number 
of elderly patients with HF, many of whom will also suffer 
from concomitant ICF. The challenges facing clinicians will 
be to identify and manage patients with HF who develop 
ICF, hopefully to prevent their associated complications. 
Optimizing HF therapy in elderly patients may be beneﬁ  cial 
for cognitive function. Many opportunities exist for clini-
cian scientists to determine optimal methods of identify-
ing and managing elderly patients with HF, developing 
strategies for treating and perhaps even preventing the 
development of cognitive deﬁ  cits in this growing vulner-
able population. 
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